CL2022001722A1 - Derivados carboxi con propiedades antiinflamatorias - Google Patents

Derivados carboxi con propiedades antiinflamatorias

Info

Publication number
CL2022001722A1
CL2022001722A1 CL2022001722A CL2022001722A CL2022001722A1 CL 2022001722 A1 CL2022001722 A1 CL 2022001722A1 CL 2022001722 A CL2022001722 A CL 2022001722A CL 2022001722 A CL2022001722 A CL 2022001722A CL 2022001722 A1 CL2022001722 A1 CL 2022001722A1
Authority
CL
Chile
Prior art keywords
inflammatory properties
carboxy derivatives
carboxy
derivatives
inflammatory
Prior art date
Application number
CL2022001722A
Other languages
English (en)
Spanish (es)
Inventor
Liam Cooke Michael
Cousin David
Colin Thor Fyfe Matthew
Michael WAUGH Thomas
Ahmed Saleh
De Simone Alessio
John Teobald Barry
Original Assignee
Sitryx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sitryx Therapeutics Ltd filed Critical Sitryx Therapeutics Ltd
Publication of CL2022001722A1 publication Critical patent/CL2022001722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CL2022001722A 2019-12-23 2022-06-22 Derivados carboxi con propiedades antiinflamatorias CL2022001722A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19219531 2019-12-23
EP20162545 2020-03-11
EP20189623 2020-08-05
EP20205768 2020-11-04

Publications (1)

Publication Number Publication Date
CL2022001722A1 true CL2022001722A1 (es) 2023-03-03

Family

ID=74104118

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001722A CL2022001722A1 (es) 2019-12-23 2022-06-22 Derivados carboxi con propiedades antiinflamatorias

Country Status (30)

Country Link
US (1) US12617762B2 (enExample)
EP (2) EP4081511B3 (enExample)
JP (2) JP7679384B2 (enExample)
KR (1) KR20220119425A (enExample)
CN (1) CN115066418B (enExample)
AU (1) AU2020412853A1 (enExample)
BR (1) BR112022011933A2 (enExample)
CA (2) CA3161424C (enExample)
CL (1) CL2022001722A1 (enExample)
CO (1) CO2022008652A2 (enExample)
CR (1) CR20220300A (enExample)
DK (1) DK4081511T6 (enExample)
EC (1) ECSP22049370A (enExample)
ES (1) ES2987014T7 (enExample)
FI (1) FI4081511T6 (enExample)
HR (1) HRP20241378T4 (enExample)
HU (1) HUE068571T2 (enExample)
IL (1) IL293982B2 (enExample)
JO (1) JOP20220162A1 (enExample)
LT (1) LT4081511T (enExample)
MA (1) MA58170B1 (enExample)
MD (1) MD4081511T2 (enExample)
MX (1) MX2022007846A (enExample)
PE (1) PE20221584A1 (enExample)
PH (1) PH12022551546A1 (enExample)
PL (1) PL4081511T6 (enExample)
RS (1) RS66019B1 (enExample)
SI (1) SI4081511T2 (enExample)
TW (1) TWI891696B (enExample)
WO (1) WO2021130492A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287444B2 (en) 2019-04-30 2024-09-01 Sitryx Therapeutics Ltd Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
US12678419B2 (en) 2020-10-27 2026-07-14 Sitryx Therapeutics Limited Compounds
WO2022229617A1 (en) * 2021-04-26 2022-11-03 Sitryx Therapeutics Limited 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2022269251A1 (en) * 2021-06-22 2022-12-29 Sitryx Therapeutics Limited Acrylamide derivatives useful as anti-inflammatory agents
CN113499453B (zh) * 2021-07-20 2022-10-21 徐州医科大学 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用
WO2023017269A1 (en) 2021-08-11 2023-02-16 Sitryx Therapeutics Limited Derivatives of itaconic acid and their use as anti-inflammatory agents
WO2023247958A1 (en) 2022-06-22 2023-12-28 Sitryx Therapeutics Limited Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases
WO2024089421A1 (en) 2022-10-25 2024-05-02 Sitryx Therapeutics Limited Tetrazole derivatives
AU2023392783A1 (en) * 2022-12-15 2025-06-19 Sitryx Therapeutics Limited Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
KR102864655B1 (ko) * 2023-01-19 2025-09-29 대한민국 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물
CN115819186B (zh) * 2023-02-14 2023-05-16 广东银珠医药科技有限公司 一种3,5-二氯苯甲醇的新型制备方法
CN117205194A (zh) * 2023-05-10 2023-12-12 苏州大学 衣康酸或其衍生物在制备预防或治疗急性移植物抗宿主病药物中的应用
CN116725998A (zh) * 2023-07-20 2023-09-12 中国科学技术大学 特立氟胺在抑制nlrp3炎症小体活化中的应用
CN118812769B (zh) * 2024-07-02 2025-09-26 南京工业大学 一种衣康酰肼诱导的Janus结构聚合物表皮贴片电极及其制备方法
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用
CN120585811B (zh) * 2025-08-07 2026-01-06 华南理工大学 4-辛基衣康酸在制备改善肺动脉高压的药物中的应用
CN121668151A (zh) * 2026-02-11 2026-03-17 武汉大学人民医院(湖北省人民医院) 衣康酸类化合物在制备治疗视网膜动脉阻塞药物中的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963672A1 (de) 1969-12-19 1971-06-24 Hoechst Ag Dithiophosphorsaeureester,ihre Herstellung und Anwendung als Schaedlingsbekaempfungsmittel
DE2047465A1 (de) 1970-09-26 1972-03-30 Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt Neue Oxdiazole und Verfahren zu lh rer Herstellung
NL7413713A (nl) 1973-11-02 1975-05-07 Ciba Geigy Werkwijze voor het bereiden van nieuwe esters.
DE2805756A1 (de) 1978-02-10 1979-08-16 Bayer Ag N-azolylalkyl-aniline sowie verfahren zu ihrer herstellung
JPS6212776A (ja) 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk ロ−ダニン誘導体
EP0521622B1 (en) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
EP0724573A1 (en) * 1993-10-20 1996-08-07 PHARMACIA & UPJOHN COMPANY Pyrimidinones as antiarthritic and anti-inflammatories
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
KR100538968B1 (ko) 1997-02-18 2006-07-11 후지 샤신 필름 가부시기가이샤 포지티브감광성조성물
US5965718A (en) 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin
JP2001354625A (ja) 2000-04-12 2001-12-25 Dainippon Ink & Chem Inc 新規なイタコン酸エステル及びその製造方法
JP4102014B2 (ja) 2000-10-03 2008-06-18 富士フイルム株式会社 感光性平版印刷版
JP2004315791A (ja) 2003-03-28 2004-11-11 Tokyo Ohka Kogyo Co Ltd ジカルボン酸モノエステル化合物およびその製造方法ならびに重合体
TW201206429A (en) 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
US8637536B2 (en) * 2010-12-06 2014-01-28 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
EP3416634A4 (en) 2016-02-15 2019-10-09 Artyomov, Maxim IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF
US20200375929A1 (en) 2017-08-14 2020-12-03 Washington University Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response
WO2019066827A1 (en) 2017-09-27 2019-04-04 Intel Corporation CHARACTERISTICS AND APPROACHES TO GRID ASSISTANCE FOR ELECTRON BEAM DIRECT WRITE LITHOGRAPHY (EBDW)
EP3813815B1 (en) 2018-06-29 2026-01-28 Ergon Pharmaceuticals, LLC Compositions and methods of using itaconic acid derivatives
IL287444B2 (en) 2019-04-30 2024-09-01 Sitryx Therapeutics Ltd Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response
US20200377510A1 (en) * 2019-05-30 2020-12-03 Auransa Inc. Derivatives of piperlongumine and uses thereof
CN110731955B (zh) 2019-10-28 2023-05-02 中山大学 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用
EP4192821A1 (en) 2020-08-05 2023-06-14 Sitryx Therapeutics Limited Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties
EP4200275A2 (en) 2020-08-21 2023-06-28 Sitryx Therapeutics Limited Fumarate derivatives and their medical use
US12678419B2 (en) 2020-10-27 2026-07-14 Sitryx Therapeutics Limited Compounds
EP4237408A1 (en) 2020-10-29 2023-09-06 Sitryx Therapeutics Limited Itaconic acid derivatives
EP4237404A1 (en) 2020-10-29 2023-09-06 Sitryx Therapeutics Limited Novel compounds

Also Published As

Publication number Publication date
PL4081511T4 (pl) 2024-12-09
TWI891696B (zh) 2025-08-01
ES2987014T3 (es) 2024-11-13
EP4081511B3 (en) 2026-03-04
JP2025131581A (ja) 2025-09-09
BR112022011933A2 (pt) 2022-09-06
FI4081511T3 (fi) 2024-10-24
EP4081511A1 (en) 2022-11-02
TW202138356A (zh) 2021-10-16
WO2021130492A1 (en) 2021-07-01
AU2020412853A1 (en) 2022-05-26
PL4081511T6 (pl) 2026-06-01
DK4081511T3 (da) 2024-09-23
CR20220300A (es) 2022-08-23
PL4081511T3 (pl) 2024-11-25
KR20220119425A (ko) 2022-08-29
FI4081511T6 (fi) 2026-06-09
CO2022008652A2 (es) 2022-07-19
CA3280359A1 (en) 2026-03-02
LT4081511T (lt) 2024-10-25
IL293982B1 (en) 2025-04-01
HUE068571T2 (hu) 2025-01-28
SI4081511T1 (sl) 2024-12-31
JOP20220162A1 (ar) 2023-01-30
EP4442319A2 (en) 2024-10-09
SI4081511T2 (sl) 2026-06-30
DK4081511T6 (da) 2026-05-26
HRP20241378T1 (hr) 2025-01-03
MA58170B1 (fr) 2024-10-31
PH12022551546A1 (en) 2023-05-03
US12617762B2 (en) 2026-05-05
CA3161424A1 (en) 2021-07-01
HRP20241378T4 (hr) 2026-06-19
MD4081511T2 (ro) 2025-01-31
ECSP22049370A (es) 2022-07-29
CA3161424C (en) 2025-10-21
JP7679384B2 (ja) 2025-05-19
US20230219907A1 (en) 2023-07-13
EP4081511B1 (en) 2024-07-31
JP2023508142A (ja) 2023-03-01
RS66019B1 (sr) 2024-11-29
CN115066418B (zh) 2025-09-05
IL293982A (en) 2022-08-01
CN115066418A (zh) 2022-09-16
EP4442319A3 (en) 2025-01-15
IL293982B2 (en) 2025-08-01
MX2022007846A (es) 2022-07-19
PE20221584A1 (es) 2022-10-06
ES2987014T7 (en) 2026-06-24

Similar Documents

Publication Publication Date Title
CO2022008652A2 (es) Derivados carboxi con propiedades antiinflamatorias
ECSP21086530A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable
CY1125110T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
EA201691194A1 (ru) Стимуляторы ргц
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
MX2022007801A (es) Formas polimorficas de rad1901-2hcl.
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
MX384244B (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
BR112022011147A2 (pt) Compostos para inibir fatores de neovascularização e uso dos mesmos
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
MX383975B (es) Derivado de anillo fusionado como inhibidor del receptor a2a
CR20160133A (es) Derivados de fenilalanina sustituidos
MX379437B (es) Derivados de hidrazina-bencilo sustituidos, como inhibidores de ppp1r15a y ppp1r15b, y el uso de los mismos para el tratamiento de trastorno de proteostasis.
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
MX2019002166A (es) Agonistas del receptor cxcr3.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
UA41582S (uk) Серветниця